To include your compound in the COVID-19 Resource Center, submit it here.

MODAG raises €12M series A to test approach to neurodegeneration

Six years after its formation, neurodegeneration company MODAG hopes to use its new €12 million ($13.7 million) series A round to test its disease-modifying approach to

Read the full 269 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE